Natural Killer Cells explains the importance of killer cells and how they are produced. It mentions that the most likely explanation for killer cell production is that they serve as a complementary system for T cells as a primary defense against viruses. However, these cells defend against certain viruses only, such as herpes viruses and influenza viruses.
The book also explains the primary functions of killer cells, and it discusses how these cells help recognize damaged tissues, limit further damage to tissues, and regenerate damaged tissues. It discusses how these cells mature and develop, and it covers the different isolation, culture, and propagation methods of these cells. Furthermore, it focuses on the different killer cells that are present in various parts of the human body.
The book concludes by explaining that natural killer cells are utilized for clinical therapy of malignancies, and that they have led to positive outcomes in the field of biology and medicine.
- Provides a broad, detailed coverage of the biology and interactions of NK cells for students, fellows, scientists, and practitioners
- Includes figures, histologic sections, and illustrations of the ontogeny of NK cells
Inhaltsverzeichnis
1;Front cover;1 2;Natural killer cells: Basic Science and Clinical Application;4 3;Copyright page;5 4;Contents;6 5;Contributors;10 6;Foreword;14 7;Preface;20 8;PART I: NK biology;24 8.1;Chapter 1 Developmental stages and pathways of NK cell maturation;26 8.1.1;The early events in hematopoiesis;26 8.1.2;NK cells as a distinct cell type;27 8.1.3;Lineage specific growth factors;27 8.1.4;Sites of NK development: the importance of the developmental environment;28 8.1.5;Fate determining interactions with stroma;29 8.1.6;Transcription factors involved in NK cell differentiation;30 8.1.7;Second messenger signalling in NK cell development;33 8.1.8;The NK cell ontogenylessons from evolution;34 8.1.9;Lessons from embryogenesis;35 8.1.10;Lessons from NK cell immune reconstitution after hematopoietic cell transplantation;35 8.1.11;Stages of NK cell development;36 8.1.12;Acquisition of inhibitory receptors during NK cell development;37 8.1.13;Linear and branching models of human NK cell development;38 8.1.14;Boundaries of NK cell lineage;39 8.1.15;Summary;40 8.2;Chapter 2 Developmental origins of thymus-derived natural killer cells;48 8.2.1;Introduction;48 8.2.2;Fetal thymic NK cell ontogeny;49 8.2.3;Early thymus-independent stages of fetal NK cell development;51 8.2.4;Dispelling the NK1.1 expression myth: NKR-P1B precedes NKR-P1C during NK lineage specification;51 8.2.5;NK-lineage specification versus commitment;52 8.2.6;NK1.1[sup(+)]CD117[sup(+)]CD90[sup(+)] precursors and their relationship to thymic NK cells;54 8.2.7;NK cell development in vivo: developmental stages versus subsets of differentiation;55 8.2.8;Composite phenotype of fetal versus adult thymic NK cells;57 8.2.9;TNK cells: physiological bipotent progenitor or lymphoid tissue inducer (LTi)-like cell?;58 8.2.10;Concluding remarks;58 8.2.11;Acknowledgements;59 8.2.12;References;59 8.3;Chapter 3 Interferon-producing killer dendritic cells (IKDC);64 8.3.1;NK antigen-presenting cells;65 8.3.2;Interferon-producing killer
dendritic cells;65 8.3.3;IKDC, a unique link between innate and adaptive immunity;71 8.3.4;Translational implications and concluding remarks;73 8.3.5;References;74 8.4;Chapter 4 Natural killer cells in cancer;78 8.4.1;Introduction;78 8.4.2;NK cells in the host response against tumours;78 8.4.3;Treating patients with adoptive transfer of NK cells;82 8.4.4;Acknowledgements;84 8.4.5;References;84 8.5;Chapter 5 NK cell immune recognition: NKG2D ligands and stressed cells;88 8.5.1;Introduction;88 8.5.2;NKG2D receptor;89 8.5.3;NKG2D ligand family members: structure and function;90 8.5.4;NKG2D ligands are inducible: role in cancer;92 8.5.5;Tumour immune evasion;92 8.5.6;Role of NKG2D in infection;93 8.5.7;NKG2D and disease;95 8.5.8;NKG2D in graft and transplantation;96 8.5.9;Acknowledgement;96 8.5.10;References;97 8.6;Chapter 6 NK cell KIR heterogeneity and evolution;102 8.6.1;The roles of MHC class I inhibitory receptors in NK cell function;103 8.6.2;Human KIR variation;103 8.6.3;Human NK cell repertoires;109 8.6.4;NK cell heterogeneity as a common feature in mammalian NK cell systems;112 8.6.5;Impact of KIR diversity on human health and disease;112 8.6.6;References;113 8.7;Chapter 7 Signalling events in natural killer cells;118 8.7.1;Introduction;118 8.7.2;Inhibitory NK receptors;119 8.7.3;Activating NK receptors;120 8.7.4;Signalling for NK-cell recruitment;126 8.7.5;Signals involved in NK-mediated immunoediting;129 8.7.6;References;131 8.8;Chapter 8 Human natural killer cell development;136 8.8.1;Introduction;136 8.8.2;Stages of human NK development;137 8.8.3;The location of human NK development;137 8.8.4;Diversity in development and function;139 8.8.5;Cytokines driving development;140 8.8.6;Gene regulation of NK cell development;140 8.8.7;NK education and regulation beyond final maturation;142 8.8.8;Conclusion;143 8.8.9;Acknowledgements;143 8.8.10;References;143 9;PART II: NK interactions with other cells;146 9.1;Chapter 9 Isolation, culture and propagation of natural
killer cells;148 9.1.1;Introduction;148 9.1.2;Isolation of NK cells;149 9.1.3;Activation and expansion of NK cells;153 9.1.4;Conclusions;156 9.1.5;Financial support;157 9.1.6;References;157 9.2;Chapter 10 The localization and migration of natural killer cells in health and disease;160 9.2.1;Introduction;160 9.2.2;NK cells in secondary lymphoid organs;161 9.2.3;NK cells in other organs;163 9.2.4;NK cell migration;166 9.2.5;Do NK cells traffic?;170 9.2.6;Concluding remarks;171 9.2.7;References;171 9.3;Chapter 11 Receptors on NK cells;178 9.3.1;Inhibitory NK receptors;179 9.3.2;Activating NK receptors;183 9.3.3;Summary;188 9.3.4;References;188 9.4;Chapter 12 Development and testing of NK cell lines;192 9.4.1;Establishing an NK cell line as a clinical-grade product;193 9.4.2;Targeting of NK cell lines to tumours;196 9.4.3;Transfecting IL-2 and FcR into NK cell lines;196 9.4.4;References;197 9.5;Chapter 13 NK cell-derived cytokines and delivery: NK cell synapses;200 9.5.1;Cytokine production by NK cell subsets;200 9.5.2;Cytokine secretion pattern of decidual NK cells;201 9.5.3;Stimuli inducing cytokine secretion by NK cells;202 9.5.4;The NK cell immune synapse;203 9.5.5;NKDC synapse;204 9.5.6;DC-mediated NK cell activation;205 9.5.7;NK cell-mediated DC activation;207 9.5.8;References;208 9.6;Chapter 14 NK cells as recipients of cytokine signals;212 9.6.1;Introduction;212 9.6.2;Cells influencing NK behaviour;213 9.6.3;Cytokines that affect NK cells;213 9.6.4;Other cytokine effects;219 9.6.5;Effector signalling pathways;219 9.6.6;Conclusion;220 9.6.7;References;220 9.7;Chapter 15 NK cells and chemokines;226 9.7.1;Introduction;226 9.7.2;Chemokine receptor expression by NK cells and chemokine-regulated NK cell functions in vitro;228 9.7.3;Signalling events controlling chemokine-regulated NK cell functions;230 9.7.4;In vivo regulation of NK cell functions by chemokines;231 9.7.5;Conclusions;233 9.7.6;Acknowledgements;233 9.7.7;References;234 9.8;Chapter 16 Natural killer cyt
olytic activity;238 9.8.1;Introduction;238 9.8.2;NK cell subsets and localization;239 9.8.3;Granule exocytosis model overview;239 9.8.4;Lytic granule components;240 9.8.5;Pore delivery model;243 9.8.6;Consequences of perforin deficiency;243 9.8.7;Granzyme-deficient mice;245 9.8.8;Death-receptor mediated cytotoxicity;245 9.8.9;Immunological consequences of NK cytotoxicity;246 9.8.10;References;247 9.9;Chapter 17 Illuminating intranodal natural killer cell behaviour using two-photon microscopy;252 9.9.1;NK cell development and tissue distribution;252 9.9.2;NK cell recruitment to LN;253 9.9.3;NK cell distribution within LN;253 9.9.4;Imaging intranodal NK cell dynamics;255 9.9.5;Cognate NKtarget cell interactions;256 9.9.6;Imaging NKDC interactions;257 9.9.7;Concluding remarks;258 9.9.8;Acknowledgements;258 9.9.9;References;258 9.10;Chapter 18 Dendritic cells and NK cells;262 9.10.1;Dendritic cells: the professional antigen-presenting cell;263 9.10.2;DC heterogeneity and hematopoietic development;265 9.10.3;DCs: lymphoid and/or myeloid origin?;265 9.10.4;Functional niches for DC subsets;266 9.10.5;Direct instructions from pathogens: DC activation through PRRs;266 9.10.6;Indirect instructions: DC activation through endogenous 'danger' signals;266 9.10.7;Killer DCs: another function for DCs;267 9.10.8;DC activation of NK cells through cell-to-cell contact;267 9.10.9;DC activation of NK cells by soluble factors;268 9.10.10;Role of killer effector cells in determining DC-mediated polarized immune responses;269 9.10.11;Reverse 'help' from NK cells;269 9.10.12;DC: NK crosstalk in peripheral tissues;269 9.10.13;DCNK crosstalk in lymph nodes;270 9.10.14;Exploiting NK 'helper'/DC1 driving function in cancer;270 9.10.15;References;272 9.11;Chapter 19 NK and NKT cells: the innateadaptive interface including humoral responses;278 9.11.1;Introduction;278 9.11.2;Functions of NK cells;279 9.11.3;Conclusions regarding the role of NK cells in regulating adaptive immune responses;285 9.1
1.4;NKT cells;286 9.11.5;NKT cell characterization, tissue and species distribution;286 9.11.6;NKT cell development;287 9.11.7;NKT cell mechanisms of action;288 9.11.8;CD1d regulates NKT cell tolerance and pathogenesis;289 9.11.9;Functional subsets of NKT cells;291 9.11.10;Conclusion;292 9.11.11;References;293 9.12;Chapter 20 NK cell and endothelial cell interactions;302 9.12.1;NK cell tissue distribution;302 9.12.2;Conclusion;308 9.12.3;Acknowledgements;309 9.12.4;References;309 9.13;Chapter 21 Natural killer cell/epithelial interactions;312 9.13.1;Phenotype of NK cells;312 9.13.2;Chemokine receptors of NK Cell;313 9.13.3;Adhesion molecules on NK cells;313 9.13.4;NK cell distribution and characteristics in normal skin in mouse and human;313 9.13.5;Abnormalities in NK cell distribution, activity and number in inflamed skin;314 9.13.6;NK cellkeratinocyte interactions;314 9.13.7;The role of NK cells in psoriasis;314 9.13.8;NK cells and allergic contact hypersensitivity;315 9.13.9;NK cells and the hair follicle epithelium in health and disease;315 9.13.10;Epithelium of the kidney and NK cells;316 9.13.11;Waldeyer's ring and NK cells;316 9.13.12;Airway epithelial cells and NK cells;316 9.13.13;Conclusions;317 9.13.14;References;317 9.14;Chapter 22 NK cellT cell interactions;320 9.14.1;Introduction;320 9.14.2;T lymphocyte populations;321 9.14.3;NK cell populations;321 9.14.4;NK cell cytokine production and T cell activation;322 9.14.5;NK cells as antigen-presenting cells;323 9.14.6;NK cell-mediated killing as a means of controlling T cell responses;324 9.14.7;T cell effects on NK cells;325 9.14.8;Conclusion;326 9.14.9;Acknowledgements;326 9.14.10;References;326 10;PART III: NK cells in the tissues;332 10.1;Chapter 23 NK cells and NKT cells in cutaneous disorders;334 10.1.1;Introduction;334 10.1.2;Allergic contact dermatitis;336 10.1.3;Psoriasis;337 10.1.4;Atopic dermatitis;338 10.1.5;UV-induced cutaneous immune suppression;339 10.1.6;Cutaneous lymphomas;340 10.1.7;Conclu
sions;340 10.1.8;References;341 10.2;Chapter 24 Natural killer cells in the respiratory tract;344 10.2.1;Introduction;344 10.2.2;Cancer;345 10.2.3;Infectious diseases;345 10.2.4;Other inflammatory lung diseases;348 10.2.5;References;349 10.3;Chapter 25 Intestinal natural killer cells;354 10.3.1;Introduction;354 10.3.2;Identification of cytotoxic NK cells in the small and large intestine;355 10.3.3;Studies on human intestinal epithelial lymphocytes;355 10.3.4;Studies on human lamina propria lymphocytes;356 10.3.5;An NKp44[sup(+)] NK cell population in the human gut;356 10.3.6;Animal studies;357 10.3.7;Rat intestinal NK cells;357 10.3.8;NK cells in the amphibian and avian gut;358 10.3.9;Origins of NK cells in intestinal tissue;358 10.3.10;NK lymphoid progenitor cells in the gut;358 10.3.11;Alternative role for NK cells in 'wound healing' in intestinal tissues;359 10.3.12;Commensal microflora and pathways to activation of NK cells in the healthy intestine;360 10.3.13;Intestinal NK cells and enteric pathogens;361 10.3.14;Human immunodeficiency virus (HIV) infection and intestinal NK cells;361 10.3.15;Conclusions;364 10.3.16;References;364 10.4;Chapter 26 Natural killer cells in the liver;368 10.4.1;Introduction;368 10.4.2;Location of NK cells in the liver;369 10.4.3;Development of liver NK cells;369 10.4.4;References;375 10.5;Chapter 27 Natural killer cells in the spleen and lymph node;382 10.5.1;Introduction;382 10.5.2;Homing of lymphocytes to the LN at steady state;383 10.5.3;Homing of lymphocytes to the spleen at steady state;384 10.5.4;Lymphocyte migration within spleen and LN T-cell areas at steady state;384 10.5.5;NK cells in LN and spleen T-cell areas at steady state;385 10.5.6;Spleen and LNs in NK cell development and homeostasis;385 10.5.7;Regulatory role of CD4[sup(+)]CD25[sup(+)]Foxp3[sup(+)] T cells in NK cell activation in the LN in steady state;386 10.5.8;The inflamed LN and spleen;387 10.5.9;NK cell recruitment to the inflamed LN and spleen;387 10.5.10;Re
cruitment of circulating NK cells to inflamed LN and spleen T-cell areas is CXCR3-dependent;388 10.5.11;Activated and immigrating DCs as the potential source of CXCL3-ligands;389 10.5.12;Induced recruitment of NK cells to an inflamed LN provides IFN-gamma for T[sub(H)]1 priming;389 10.5.13;DC-mediated priming of NK cells leads to effector NK cell release into the circulation;390 10.5.14;References;391 10.6;Chapter 28 Nature killer cells in the central nervous system;396 10.6.1;Homing of NK cells into the CNS;396 10.6.2;NK cell-mediated neuron, oligodendrocyte and glial cell damage;397 10.6.3;NK cells in infection of the CNS;398 10.6.4;NK cells and tumour immune surveillance of the CNS;400 10.6.5;Regulatory functions of NK cells in CNS inflammation and autoimmunity;402 10.6.6;Summary and future research directions;403 10.6.7;Acknowledgements;404 10.6.8;References;404 10.7;Chapter 29 NK cells in the eye;408 10.7.1;Introduction;408 10.7.2;Immune privilege of the eye;409 10.7.3;Anatomical and structural properties of the eye that limit immune-mediated responses;410 10.7.4;Anti-inflammatory and immunosuppressive soluble factors in the eye;411 10.7.5;Cell membrane-bound factors that contribute to immune privilege;411 10.7.6;ACAID: A dynamic immunoregulatory process that sustains immune privilege in the eye;412 10.7.7;Ocular immune privilege and NK cells;413 10.7.8;Role of NK cells in bacterial, viral and neoplastic diseases of the eye;413 10.7.9;Conclusions;419 10.7.10;References;419 10.8;Chapter 30 NK cells and reproduction;426 10.8.1;Introduction;426 10.8.2;History and terminology;427 10.8.3;Uterine NK cells and the menstrual cycle;428 10.8.4;The origin of uterine NK cells;429 10.8.5;Phenotype of uterine NK cells;429 10.8.6;Function of uterine NK cells;431 10.8.7;Potential ligands for NK cells on trophoblast;433 10.8.8;Concluding remarks;436 10.8.9;References;436 10.9;Chapter 31 Identification of natural killer cells in tissues and their isolation;440 10.9.1;Introductio
n;440 10.9.2;NK cell subsets;441 10.9.3;NK cells in normal tissues;442 10.9.4;NK cells in disease;446 10.9.5;References;451 10.10;Chapter 32 Natural killer cell immune regulation: coordination of immune function in tissues;456 10.10.1;Introduction;456 10.10.2;Cellular interactions in innate immune responses;457 10.10.3;NK cell activation at inflammatory sites: role of receptorligand interactions and of TLRs;457 10.10.4;NKDC interactions: NK cell-mediated killing of immature myeloid DCs (DC 'editing');458 10.10.5;NK cell-promoted maturation of myeloid DCs;458 10.10.6;Role of cytokine microenvironment in the modulation of innate and adaptive immune responses;459 10.10.7;NK cell interactions with mast cells: regulatory effects on the innate immunity;459 10.10.8;NK cells interaction with PDCs;461 10.10.9;Conclusions;461 10.10.10;Acknowledgements;462 10.10.11;References;462 11;PART IV: NK cells in disease;466 11.1;Chapter 33 Natural killer cells and transplantation;468 11.1.1;Introduction;468 11.1.2;Heart transplantation;469 11.1.3;Lung transplantation;470 11.1.4;Small bowel transplantation;471 11.1.5;Liver transplantation;471 11.1.6;Kidney transplantation;471 11.1.7;Skin transplantation;472 11.1.8;Pancreatic islet transplantation;473 11.1.9;Xenotransplantation;473 11.1.10;Chemokine-directed NK cell allograft infiltration;474 11.1.11;Transplantation immunotherapies and NK cell function;475 11.1.12;Conclusions;478 11.1.13;References;478 11.2;Chapter 34 Natural killer cells and autoimmunity;484 11.2.1;Introduction;484 11.2.2;Genetic association of NK cell receptor variation with autoimmune disease;485 11.2.3;Functional characteristics and models of NK cells in autoimmune diseases;485 11.2.4;Influence of NK cells on autoimmune T cell polarization;486 11.2.5;NK cell editing of myeloid cells;487 11.2.6;Direct targeting of autoimmune lymphocytes by NK cells;487 11.2.7;Summary;488 11.2.8;Acknowledgements;488 11.2.9;References;488 11.3;Chapter 35 Interaction of NK cells with bac
teria;492 11.3.1;Introduction;492 11.3.2;Host defence by NK cells;493 11.3.3;Recognition of pathogens by PRRs;493 11.3.4;Crosstalk between NK cells and DCs;494 11.3.5;Regulation of Th1 immunity by lactic acid bacteria;494 11.3.6;The mechanism of NK and NKT activation by glycolipid α-GalCer;496 11.3.7;NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity byα-GalCer in vivo;496 11.3.8;Application of immunological theory to cancer immunotherapy and activation of innate immunity for cancer therapy;498 11.3.9;Activation of acquired immunity for cancer therapy using bacterial adjuvants;498 11.3.10;Conclusions;499 11.3.11;References;500 11.4;Chapter 36 Natural killer cells and human immunodeficiency virus;504 11.4.1;Introduction;505 11.4.2;Infection of NK cells by HIV-1;505 11.4.3;Effect of HIV-1 viraemia on NK cells;506 11.4.4;Interactions between NK cells and autologous DCs in HIV-1 infection;512 11.4.5;Effect of ART on NK cell phenotype and functions;513 11.4.6;Modulation of NK cell effector function in response to cytokines during HIV-1 infection;513 11.4.7;NK cells and resistance to HIV-1 infection;514 11.4.8;Genetic factors associated with a positive NK cell-mediated clinical outcome of HIV-1 infection;515 11.4.9;Future perspective;516 11.4.10;Acknowledgements;517 11.4.11;References;517 11.5;Chapter 37 Cytomegalovirus infection and NK cells;522 11.5.1;Cytomegalovirus;522 11.5.2;The role of NK cells in CMV infection;523 11.5.3;NK cell activation in CMV infection;525 11.5.4;Viral evasion of NK cell responses;526 11.5.5;NK cells can regulate anti-viral adaptive immune responses;528 11.5.6;Conclusion and perspectives;529 11.5.7;References;531 11.6;Chapter 38 Natural killer cells in allergy;534 11.6.1;Pathogenesis of allergic disease;534 11.6.2;Regulatory role of NK cells in allergy;535 11.6.3;NK subsets with regulatory function;535 11.6.4;NK cells in the lymph node;536 11.6.5;NKDC crosstalk in allergy;536
11.6.6;NK cells and T cells;536 11.6.7;NK cells and eosinophils;536 11.6.8;NK cells and asthma;537 11.6.9;NK cells and atopic dermatitis;537 11.6.10;Concluding remarks;538 11.6.11;References;538 11.7;Chapter 39 Natural killer cells in wound healing;542 11.7.1;Wound healing;542 11.7.2;Conclusions;547 11.7.3;Acknowledgements;547 11.7.4;References;547 11.8;Chapter 40 Natural killer cells in atherosclerosis;550 11.8.1;NK cells in murine atherosclerosis;551 11.8.2;Conclusion;554 11.8.3;Acknowledgements;554 11.8.4;References;554 11.9;Chapter 41 Natural killer cells in leukaemia;556 11.9.1;Introduction;556 11.9.2;NK cells as effectors of antileukaemia activity;557 11.9.3;NK cells in acute leukaemia;557 11.9.4;NK cells in chronic leukaemia;559 11.9.5;NK cells and CLL;560 11.9.6;NK cells in myelodysplasia;560 11.9.7;NK cells in chronic myeloproliferative disorders;561 11.9.8;Immunotherapy;561 11.9.9;Conclusions;562 11.9.10;Acknowledgements;562 11.9.11;References;562 11.10;Chapter 42 Natural killer cells and allogeneic haematopoietic cell transplantation;566 11.10.1;Introduction;566 11.10.2;NK cell alloreactivity in allogeneic HCT: pre-clinical data;568 11.10.3;Donor-versus-recipient NK cell alloreactivity in allogeneic HCT;568 11.10.4;Guidelines for NK alloreactive donor selection;571 11.10.5;Another NK cell effect in transplantation: the missing ligand model;571 11.10.6;Do activating KIRs play a role in transplantation?;572 11.10.7;Conclusions;572 11.10.8;Acknowledgements;573 11.10.9;References;573 11.11;Chapter 43 Clinical trials of NK cells for cancer;578 11.11.1;Introduction;579 11.11.2;Biologic basis of NK cell-mediated therapies;579 11.11.3;Therapeutic applications for NK cells;581 11.11.4;Clinical-scale GMP production and expansion of human NK cells;585 11.11.5;Summary;588 11.11.6;References;589 11.12;Chapter 44 Natural killer cells and hepatitis C virus infection;594 11.12.1;Introduction;595 11.12.2;Hepatitis C virus;595 11.12.3;Host response to HCV infection;597 11.
12.4;Current therapy of HCV infection;605 11.12.5;Acknowledgement;605 11.12.6;References;606 11.13;Chapter 45 Natural killer cells and the biology of parasitism;612 11.13.1;Introduction;612 11.13.2;Malaria;613 11.13.3;Toxoplasma gondii;615 11.13.4;Leishmaniasis;617 11.13.5;Trypansoma cruzi;618 11.13.6;Helminths;619 11.13.7;Conclusion;620 11.13.8;References;620 11.14;Chapter 46 Lymphoproliferative disorders of natural killer cells;624 11.14.1;Introduction;624 11.14.2;WHO recognized NK cell neoplasms;625 11.14.3;Inter-relation of the WHO recognized NK cell neoplasms;632 11.14.4;References;634 12;PART V: Special topics in NK biology;638 12.1;Chapter 47 Natural killer cell induction of tolerance;640 12.1.1;NK cell self-tolerance;641 12.1.2;Non-MHC-class-Ispecific NK-cell recognition;644 12.1.3;NK cells in regulation of immune responses;645 12.1.4;References;651 12.2;Chapter 48 Genetic engineering of natural killer cells;656 12.2.1;Introduction;656 12.2.2;Expression of transgenes by primary NK cells and NK cell lines;657 12.2.3;Adenoviral transduction of primary, IL-2-activated NK cellsmarker genes;658 12.2.4;A-NK cell transductioncytokine genesIL-2;658 12.2.5;IL-12 gene transduction enhances IFN[sub(γ)] production and CD25 expression by NK cells;659 12.2.6;Reduced need for exogenous IL-2 support by A-NK cells transduced to express IL-12;660 12.2.7;Superior antitumour effect by A-NK[sub(12)] cells compared to A-NK[sub(mock)] cells;661 12.2.8;Local IL-12 production benefits 'bystander' nontransduced A-NK cells;661 12.2.9;IL-12 induced host production of IFN[sub(γ)] is essential for the antitumour effects of A-NK[sub(12)] cells;663 12.2.10;Transduction of A-NK cells to express both IL-12 and TNFα;664 12.2.11;Simultaneous transduction of NK cells with IL-12 and IL-2 genes eliminates the need for exogenous IL-2;665 12.2.12;Promising outlook for genetically engineered NK cells;665 12.2.13;References;666 12.3;Chapter 49 NK cell-mediated target cell death;668 12.
3.1;Introduction;668 12.3.2;Cell-mediated cytotoxicity;669 12.3.3;Death-associated proteolytic activities in target cells as a measure of effector cell lethality;671 12.3.4;Antibody-dependent cellular cytotoxicity;672 12.3.5;Conclusions;673 12.3.6;References;673 12.4;Chapter 50 NK-cell tracking using non-invasive imaging modalities;676 12.4.1;Introduction;676 12.4.2;Routes for NK-cell administration;678 12.4.3;Imaging techniques for tracking of NK cells;678 12.4.4;Optical imaging for tracking of NK-cell immunotherapy;679 12.4.5;MR imaging;680 12.4.6;NK cell tracking with bifunctional contrast agents or double labelling techniques;683 12.4.7;FDG-PET imaging;683 12.4.8;Other radiotracer modalities;684 12.4.9;Translational and clinical applications;684 12.4.10;Conclusion;684 12.4.11;References;685 13;Subject index;688 13.1;A;688 13.2;B;689 13.3;C;689 13.4;D;690 13.5;E;691 13.6;F;691 13.7;G;692 13.8;H;692 13.9;I;693 13.10;J;694 13.11;K;694 13.12;L;694 13.13;M;695 13.14;N;696 13.15;O;697 13.16;P;697 13.17;R;698 13.18;S;698 13.19;T;699 13.20;U;700 13.21;V;700 13.22;W;701 13.23;X;701 13.24;Y;701 14;Colour plates section;702